{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-065107","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.224435+00:00","generated_at":"2026-06-14T13:41:27.574980+00:00","sec_items":["1.01","2.01","2.03"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura receives $150K loan from 66% owner AD Pharma; warns of possible shutdown if no more funding","bullets":["Loan from Abuse Deterrent Pharma adds to $2.32M note, total debt $3.47M at 5.25%, due Dec 31, 2023.","Also received $235K from CARES Act employee retention credit; funds expected to last through June 2023.","If additional financing not secured by end of June 2023, may scale back operations or seek bankruptcy.","AD Pharma owns ~66% of common stock; entity controlled by Mr. Schutte who holds ~14% directly.","Overdue amounts bear interest at 7.5% per annum after 5-day grace period."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-065107","json":"https://secwatch.observer/filing/0001104659-23-065107.json","markdown":"https://secwatch.observer/filing/0001104659-23-065107.md","text":"https://secwatch.observer/filing/0001104659-23-065107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/0001104659-23-065107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/tm2317061d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:41:27.574980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3decceb5fd8de44d8ae33148bb8f3405cb2b95a6","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $150,000 loan with Abuse Deterrent Pharma, LLC at 5.25% maturing December 31, 2023.","evidence_excerpt":"On May 19, 2023 we received a $150,000 loan from Abuse Deterrent Pharma, LLC (\"AD Pharma\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465923065107/0001104659-23-065107-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$150,000 loan"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}